Abstract
Aim
This study aimed to compare the effectiveness and safety of voclosporin + mycophenolate mofetil (MMF), tacrolimus + MMF, and monotherapy with MMF or cyclophosphamide as induction treatment for lupus nephritis.
Methods
The study included randomized controlled trials (RCTs) that evaluated the effectiveness and safety of voclosporin + MMF, tacrolimus + MMF, and monotherapy for induction treatment in patients with lupus nephritis. To incorporate direct and indirect evidence from RCTs, we used a Bayesian network meta-analysis.
Results
Four RCTs, including 936 participants, met the inclusion criteria. Tacrolimus + MMF substantially increased the incidence of complete remission relative to that following monotherapy (odds ratio [OR] 2.85; 95% credible interval [CrI] 1.87–4.39). Tacrolimus + MMF was also more effective than voclosporin + MMF (OR 1.43; 95% CrI 0.80–2.57). Tacrolimus + MMF showed the greatest chance of being the optimal treatment for overall response (surface under the cumulative ranking curve [SUCRA] = 0.942), followed by voclosporin + MMF (SUCRA = 0.558) and monotherapy (SUCRA = 0.001). In terms of safety based on severe event rates, monotherapy had the greatest chance of being the safest treatment (SUCRA = 0.903), followed by voclosporin + MMF (SUCRA = 0.517) and tacrolimus + MMF (SUCRA = 0.081).
Conclusion
Tacrolimus + MMF and voclosporin + MMF were more effective than monotherapy, and tacrolimus + MMF was the most effective induction treatment for lupus nephritis patients. However, tacrolimus + MMF did pose a greater risk of serious adverse events than monotherapy.
Zusammenfassung
Ziel der Arbeit
Ziel der vorliegenden Studie war es, die Wirksamkeit und Sicherheit von Voclosporin + Mycophenolat-Mofetil (MMF) zum einen, Tacrolimus + MMF zum anderen und einer Monotherapie mit MMF oder Cyclophosphamid als Induktionstherapie bei Lupusnephritis zu vergleichen.
Methoden
In die Studie wurden randomisierte kontrollierte Studien (RCT) einbezogen, in denen die Wirksamkeit und Sicherheit von Voclosporin + MMF, Tacrolimus + MMF und einer Monotherapie als Induktionstherapie bei Patienten mit Lupusnephritis verglichen wurde. Um direkte und indirekte Evidenz aus RCT zu erfassen, wurde eine Bayes-Netzwerk-Metaanalyse durchgeführt.
Ergebnisse
Von 4 RCT mit 936 Teilnehmern wurden die Einschlusskriterien erfüllt. Tacrolimus + MMF führten zu einer wesentlich erhöhten Inzidenz kompletter Remissionen im Verhältnis zur Situation nach Monotherapie (Odds Ratio [OR] 2,85; 95%-Glaubwürdigkeitsintervall, Credibility Interval [CrI] 1,87–4,39). Tacrolimus + MMF erwiesen sich auch als wirksamer denn Voclosporin + MMF (OR 1,43; 95%-CrI 0,80–2,57). Bei Tacrolimus + MMF bestand die höchste Wahrscheinlichkeit, die optimale Therapie in Bezug auf das Gesamtansprechen darzustellen (Oberfläche unter der kumulativen Ranking-Kurve [SUCRA] = 0,942), dann folgten Voclosporin + MMF (SUCRA = 0,558) und die Monotherapie (SUCRA = 0,001). In Hinsicht auf die Sicherheit, basierend auf der Rate schwerer unerwünschter Ereignisse, bestand die höchste Wahrscheinlichkeit, die sicherste Therapie darzustellen, für die Monotherapie (SUCRA = 0,903), dann folgten Voclosporin + MMF (SUCRA = 0,517) und Tacrolimus + MMF (SUCRA = 0,081).
Schlussfolgerung
Tacrolimus + MMF und Voclosporin + MMF waren wirksamer als die Monotherapie, und Tacrolimus + MMF erwies sich als die wirksamste Induktionstherapie bei Patienten mit Lupusnephritis. Allerdings war das Risiko schwerer unerwünschter Ereignisse unter Tacrolimus + MMF größer als unter Monotherapie.
Similar content being viewed by others
References
Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, Klinenberg JR (1995) Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 25:47–55
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li L‑S, Mysler E, Sanchez-Guerrero J, Solomons N (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112
Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, Shen P, Chen N (2012) Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 27:1467–1472
Sung-Eun C, Dong-Jin P, Ji-Hyoun K, Kyung-Eun L, Haimuzi X, Ji Shin L, Choi Y‑D, Shin-Seok L (2019) Comparison of renal responses to cyclophosphamide and mycophenolate mofetil used as induction therapies in Korean patients with lupus nephritis. J Rheum Dis 26:57–65
Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS (2011) Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 38:69–78
Ayoub I, Rovin BH (2017) Calcineurin inhibitors in the treatment of lupus nephritis: a hare versus turtle story? J Am Soc Nephrol 28(12):3435–3437
Yo J, Barbour T, Nicholls K (2019) Management of refractory lupus nephritis: challenges and solutions. Open access rheumatology. Res Rev 11:179
Shen X, Jiang H, Ying M, Xie Z, Li X, Wang H, Zhao J, Lin C, Wang Y et al (2016) Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep 6:32087. https://doi.org/10.1038/srep32087
Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T et al (2012) Joint European league against rheumatism and European renal association—European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71(11):1771–1782
van Gelder T, Huizinga RB, Lisk L, Solomons N (2021) Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfab022
Kino T, Hatanaka H, Miyata S et al (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40:1256–1265
Rovin BH, Teng YO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397(10289):2070–2080. https://doi.org/10.1016/S0140-6736(21)00578-X
Rovin BH, Solomons N, Pendergraft WF III, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB et al (2019) A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95:219–231
Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F et al (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162(1):18–26. https://doi.org/10.7326/M14-1030
Bao H, Liu Z‑H, Xie H‑L, Hu W‑X, Zhang H‑T et al (2008) Successful treatment of class V+ IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19(10):2001–2010
Lee YH (2018) An overview of meta-analysis for clinicians. Korean J Intern Med 33:277
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. https://doi.org/10.1136/bmj.d5928
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3:110
Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897
Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171
Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:641–656
Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98–110
Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285–299
Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM et al (2011) Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol 38(1):69–78. https://doi.org/10.3899/jrheum.100130
Pan L, Lu M‑P, Wang J‑H, Xu M, Yang S‑R (2020) Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 16:19–30
Liossis SN, Staveri C (2021) What’s new in the treatment of systemic lupus erythematosus. Front Med 8:221
Naesens M, Kuypers DR et al (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508. https://doi.org/10.2215/CJN.04800908
Liao R, Liu Q, Zheng Z, Fan J, Peng W, Kong Q, He H, Yang S, Chen W et al (2015) Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis. PLoS ONE 10(7):e132724. https://doi.org/10.1371/journal.pone.0132724
Mohan S, Radhakrishnan J (2011) Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 75:233–241
Lee YH, Song GG (2019) Causal association between rheumatoid arthritis with the increased risk of type 2 diabetes: a mendelian randomization analysis. J Rheum Dis 26:131–136
Lee YH, Song GG (2020) Circulating interleukin-18 level in systemic lupus erythematosus. J Rheum Dis 27:110–115
Lee YH, Song GG (2020) Association between signal transducers and activators of transcription 4 rs7574865 polymorphism and systemic lupus erythematosus: a meta-analysis. J Rheum Dis 27:277–284
Lee YH, Song GG (2020) Circulating interleukin-37 levels in rheumatoid arthritis and systemic lupus erythematosus and their correlations with disease activity: a meta-analysis. J Rheum Dis 27:152–158
Lee YH, Song GG (2020) Associations between circulating Interleukin-17 levels and systemic lupus erythematosus and between Interleukin-17 gene polymorphisms and disease susceptibility: a meta-analysis. J Rheum Dis 27:37–44
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Y.H. Lee and G.G. Song declare that they have no competing interests.
For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.
Additional information
Redaktion
Ulf Müller-Ladner, Bad Nauheim
Uwe Lange, Bad Nauheim
Scan QR code & read article online
Rights and permissions
About this article
Cite this article
Lee, Y.H., Song, G.G. A network meta-analysis of randomized controlled trials comparing the effectiveness and safety of voclosporin or tacrolimus plus mycophenolate mofetil as induction treatment for lupus nephritis. Z Rheumatol 82, 580–586 (2023). https://doi.org/10.1007/s00393-021-01087-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-021-01087-z